Definitive Contract 75N91022C00013
Award Date
5/1/22
Potential Completion Date
4/30/32
Potential Value
$165M
Federal Agency
National Cancer Institute
Awardee
Theradex Systems, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Princeton, NJ, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $36,506,288.06 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to Theradex Systems, Inc. for clinical trials monitoring services. The contract has a performance period from May 1, 2017 to April 30, 2022.
The contract supports NCI's Experimental Therapeutics Clinical Trials Network (ETCTN), National Clinical Trials Network (NCTN), and National Community Oncology Research Program (NCORP), as well as the NCI COVID-19 in Cancer Patients Study (NCCAPS) and the...
This is a $112,550,865 cost plus fixed fee contract awarded by the National Cancer Institute (NCI) to Technical Resources International, Inc. (TRI) to provide drug development support services for the Cancer Therapy Evaluation Program (CTEP). The contract has a base year plus nine option years, for a total period of performance of 10 years starting on July 1, 2022. The contract is not set aside and TRI is a minority-owned, woman-owned, Hispanic American-owned small business with significant...
The National Cancer Institute (NCI) of the National Institutes of Health awarded a $43,043,088 cost-plus-fixed-fee contract to Agile Decision Sciences, LLC, an 8(a) small disadvantaged business, for clinical data management services in support of the NCI's Center for Cancer Research (CCR) clinical trials program. The contract has a base period of one year and four one-year option periods, with a total potential value of $43,043,088 and a completion date of January 14, 2028.
As a...
This is a $150,914,306.15 cost-plus-award-fee contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Ctis, Inc., a woman-owned small business. The purpose of the contract is to develop, maintain, and expand the existing Cancer Therapy Evaluation Program - Enterprise Information System (CTEP-ESYS) to support the NCI research community and migrate toward future NCI-wide enterprise development initiatives and the...
This is a 10-year, $171,423,571 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Technical Resources International, Inc. (Technical Resources Intl) to provide clinical trials sponsor and regulatory management support services. The contract is set aside for small businesses and supports the Center for Cancer Research (CCR) within NCI, including compliance with regulations, safety monitoring, site monitoring,...
This is a $367,873.34 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to the Institute for Defense Analyses (IDA), a nonprofit research organization. The contract is for strategic priorities and support for NCI's Clinical Trials & Translational Research Advisory Committee (CTAC) for the period of June 22, 2015 to June 21, 2017, with a final completion date of February 28, 2018. The contract is not set aside for any specific business types. IDA is a Federally...
This is a $12,462,048.18 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services National Institutes of Health, to EDJ Associates, Inc. to provide support services for the Pharmaceutical Management Branch (PMB) of the Cancer Therapy Evaluation Program (CTEP).
The contract was originally awarded in May 2017 as a 5-year contract with a Woman-Owned Small Business set-aside. The services include support for drug...
This is a Cost Plus Fixed Fee definitive contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Westat, Inc., a prominent professional services firm. The contract, with a ceiling value of $2,386,684,477.18, is for the Cancer Trials Support Unit (CTSU), which provides broad-based support for cancer clinical trials. This contract does not have a set-aside designation. Westat has extensive experience working with federal agencies...
This is a $8,990,511.70 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Westat, Inc., a professional services firm based in Rockville, Maryland. The contract is part of the NCI's Cancer Trials Support Unit (CTSU) Indefinite Delivery/Indefinite Quantity (IDIQ) vehicle, which provides broad-based support for cancer clinical trials. Under this delivery order, Westat will provide administrative and other support services for the CTSU program. The...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...